thyrotropin alfa

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Thyrogen. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Thyrogen.

This EPAR was last updated on 24/11/2021

Authorisation details

Product details
Agency product number
Active substance
thyrotropin alfa
International non-proprietary name (INN) or common name
thyrotropin alfa
Therapeutic area (MeSH)
Thyroid Neoplasms
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Genzyme Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands

Product information

10/11/2021 Thyrogen - EMEA/H/C/000220 - N/0110

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Anterior pituitary lobe hormones and analogues

  • Pituitary and hypothalamic hormones and analogues

Therapeutic indication

Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone-suppression therapy (THST).

Low-risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no recombinant human (rh) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels.

Thyrogen is indicated for pre-therapeutic stimulation in combination with 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating